MarketCap
Facebook
X
Telegram
MiMedx Group Financial Ratios 2025-2009 | MDXG
Brief overview of MiMedx Group's valuation multiples
This overview follows the five latest available observations from 2016 through 2025.
The current valuation set is P/E 16.03x (median 27.72x), EV/EBITDA 77.03x (median 77.03x), P/S 1.86x (median 2.26x). Multiples are on average 40.7% below their own medians. Shares look cheaper than their recent historical valuation.
The 1/P/E calculation produces a 6.2% earnings yield. It does not capture future growth or capital structure.
Capital efficiency is characterized by ROE 18.9%, ROA 14.2%, ROCE 24.9%. Returns on capital and assets point to efficient economics and a strong internal source of growth.
The PEG ratio is 1.91x; investors pay a high price per unit of expected growth.
The time from paying for inputs to receiving cash rose from 82.9 days to 125.4 days. Cash turnover slowed.
Overall assessment
MiMedx Group's multiples are below five-year reference levels despite strong quality metrics, providing valuation cushion but not eliminating hidden risks.
Annual Financial Ratios MiMedx Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
16.0 | 27.7 | 16.4 | -17.9 | -53.2 | -21.6 | -30.9 | -9.2 | 31.8 | 2270.2 | 32.1 | 148.4 | -185.2 | -46.2 | -8.0 | -6.8 | - |
P/S |
1.9 | 3.4 | 3.0 | 2.0 | 2.3 | 4.3 | 2.6 | 0.8 | 6.4 | 4.0 | 5.0 | 7.8 | 12.9 | 13.1 | 10.4 | - | - |
EPS |
0.3 | 0.3 | 0.4 | -0.3 | -0.1 | -0.8 | -0.2 | -0.3 | 0.6 | - | 0.3 | 0.1 | -0.0 | -0.1 | -0.1 | -0.2 | - |
EV (Enterprise Value) |
699 M | 1.14 B | 968 M | 573 M | 556 M | 1.17 B | 855 M | 304 M | 2.08 B | 25.9 M | -561 K | -26.7 M | -33 M | 363 M | 92.3 M | 77.1 M | -2.65 M |
EBITDA per Share |
0.53 | 0.44 | 0.35 | -0.1 | -0.02 | -0.37 | -0.127 | 0.0283 | 0.439 | - | - | - | - | -0.043 | -0.11 | -0.16 | - |
EV/EBITDA |
8.9 | 17.6 | 23.9 | -50.3 | -669.2 | -23.7 | -58.0 | 77.0 | 39.8 | 133.9 | 33.8 | 95.0 | -757.4 | -100.2 | -10.7 | -7.6 | - |
PEG |
-0.81 | 1.91 | -0.16 | 0.62 | - | 0.1 | -1.96 | 0.06 | 0.0 | -23.01 | 0.09 | 0.65 | -3.4 | -1.39 | -0.29 | - | - |
P/B |
3.0 | 6.1 | 6.7 | 7.3 | 5.9 | -7087.2 | 23.0 | 5.6 | 27.8 | 6.7 | 8.8 | 10.3 | 10.4 | 17.7 | 6.8 | 12.7 | - |
P/CF |
10.5 | 17.8 | 35.6 | -30.3 | -276.2 | -35.1 | -19.0 | 10.7 | 35.7 | 52.7 | 77.9 | 67.6 | -230.0 | -89.3 | -11.4 | -9.5 | - |
ROE % |
18.94 | 21.97 | 40.80 | 167.87 | -12542.68 | 32856.00 | -74.36 | -60.37 | 87.71 | 0.29 | 27.27 | 6.96 | -5.59 | -38.30 | -85.71 | -187.19 | - |
ROA % |
14.18 | 16.07 | 24.36 | -17.61 | -5.47 | -24.39 | -15.30 | -24.40 | 53.38 | 0.20 | 21.67 | 5.69 | -4.85 | -21.78 | -37.64 | -155.32 | - |
ROCE % |
24.90 | 30.48 | 26.01 | 81.87 | -8598.78 | 30265.33 | -21.19 | -7.65 | 59.88 | 0.62 | 22.32 | 7.81 | -3.51 | -17.75 | -51.04 | -172.65 | - |
Current Ratio |
4.0 | 3.7 | 2.5 | 1.8 | 2.0 | 1.0 | 1.8 | 1.0 | 1.1 | 2.5 | 3.6 | 4.7 | 6.8 | 3.6 | 0.9 | 5.9 | - |
DSO |
57.3 | 57.4 | 55.0 | 56.9 | 57.1 | 49.8 | 39.5 | 0.5 | 0.7 | 110.5 | 104.8 | 82.3 | 99.3 | 103.3 | 88.9 | - | - |
DIO |
122.8 | 136.2 | 114.3 | 92.8 | 100.2 | 90.3 | 77.1 | 160.4 | 98.7 | 220.8 | 134.8 | 147.9 | 151.9 | 212.7 | 79.8 | - | - |
DPO |
54.8 | 50.0 | 58.5 | 59.8 | 74.4 | 40.7 | 73.8 | 149.1 | 88.1 | 141.7 | 119.8 | 105.5 | 97.5 | 88.1 | - | - | - |
Operating Cycle |
180.2 | 193.6 | 169.3 | 149.7 | 157.3 | 140.1 | 116.6 | 160.8 | 99.4 | 331.3 | 239.5 | 230.3 | 251.1 | 315.9 | 168.8 | - | - |
Cash Conversion Cycle |
125.4 | 143.6 | 110.8 | 89.8 | 82.9 | 99.5 | 42.8 | 11.7 | 11.3 | 189.6 | 119.7 | 124.8 | 153.7 | 227.9 | 168.8 | - | - |
All numbers in USD currency
Quarterly Financial Ratios MiMedx Group
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.1 | -0.07 | - | 0.11 | 0.07 | 0.05 | - | 0.05 | 0.12 | 0.06 | - | 0.06 | - | -0.06 | - | -0.09 | -0.11 | -0.11 | - | -0.04 | -0.03 | -0.09 | -0.17 | -0.48 | -0.08 | -0.04 | -0.07 | 0.12 | -0.16 | -0.12 | -0.34 | - | 0.02 | 0.04 | 0.04 | 0.41 | 0.1 | 0.06 | 0.05 | 0.03 | 0.02 | 0.01 | 0.13 | 0.06 | 0.05 | 0.04 | 0.04 | 0.03 | - | -0.01 | -0.01 | - | -0.01 | -0.02 | -0.01 | -0.05 | -0.01 | -0.01 | -0.04 | -0.02 | -0.03 | -0.05 |
EBITDA per Share |
-0.12 | -0.1 | - | 0.15 | 0.09 | 0.06 | - | 0.08 | 0.16 | 0.09 | - | 0.1 | 0.1 | - | - | -0.06 | -0.08 | -0.08 | - | - | 0.01 | -0.05 | - | -0.08 | -0.04 | -0.11 | - | 0.15 | -0.14 | -0.11 | - | 0.02 | 0.03 | 0.04 | - | 0.09 | 0.08 | 0.07 | - | 0.05 | 0.04 | 0.02 | - | 0.07 | 0.06 | 0.04 | - | 0.04 | - | -0.01 | - | - | -0.01 | - | - | -0.04 | - | -0.01 | - | -0.02 | -0.03 | -0.04 |
ROE % |
0.11 | 10.44 | 14.91 | 19.38 | 22.86 | 24.37 | 20.91 | 662.56 | 648.62 | 665.89 | 659.95 | 703.11 | 141.35 | 291.92 | 264.16 | 304.43 | 286.19 | 310.40 | 169.31 | 11222.64 | 24127.04 | 29746.11 | 32856.00 | 21780.93 | 8872.25 | 3178.22 | -74.36 | -125.58 | -161.93 | -108.26 | -60.37 | 18.37 | 49.65 | 53.08 | 48.42 | 54.03 | 25.61 | 20.03 | 16.28 | 43.41 | 46.98 | 50.52 | 53.41 | 19.17 | 17.24 | 11.78 | 6.96 | 0.73 | -3.83 | -4.42 | -5.59 | -11.67 | -32.34 | -35.03 | -38.30 | -51.93 | -45.69 | -63.01 | -85.69 | -14.84 | -21.04 | -28.14 |
ROA % |
-0.25 | 7.63 | 11.15 | 14.47 | 16.88 | 17.75 | 15.15 | 19.67 | 17.03 | 6.41 | 2.23 | -2.64 | -13.17 | -15.15 | -12.18 | -13.14 | -8.26 | -12.65 | -6.64 | -14.85 | -23.16 | -26.40 | -24.39 | -20.66 | -3.64 | -9.75 | -15.30 | -40.32 | -46.25 | -32.20 | -20.73 | 8.76 | 33.40 | 37.14 | 36.56 | 37.71 | 14.78 | 10.60 | 8.03 | 13.20 | 16.30 | 19.28 | 21.67 | 15.33 | 13.90 | 9.54 | 5.69 | 0.50 | -3.25 | -3.79 | -4.85 | -7.73 | -19.36 | -20.58 | -21.78 | -26.73 | -21.25 | -28.38 | -37.62 | -6.52 | -9.24 | -12.35 |
ROCE % |
-0.16 | 12.46 | 19.07 | 25.23 | 29.90 | 32.67 | 28.60 | 864.99 | 773.25 | 761.18 | 752.71 | 789.10 | 23.54 | 234.22 | 232.33 | 250.84 | 220.19 | 234.46 | 109.36 | 6580.69 | 10466.19 | 19623.11 | 19538.00 | 19579.28 | 13058.31 | 9115.32 | -47.35 | -46.60 | -84.50 | -28.89 | 10.11 | 16.31 | 20.46 | 21.88 | 15.90 | 19.43 | 15.90 | 12.11 | 7.32 | 13.53 | 15.23 | 16.49 | 15.38 | 19.56 | 12.90 | 6.67 | 2.74 | 2.39 | -2.80 | -2.67 | -1.67 | -19.83 | -20.07 | -22.22 | -21.91 | -35.80 | -37.94 | -64.73 | -61.57 | -13.89 | -20.31 | -27.37 |
Current Ratio |
4.3 | 4.7 | 4.0 | 4.0 | 3.9 | 4.0 | 3.7 | 3.9 | 3.7 | 3.4 | 2.5 | 2.0 | 1.8 | 1.8 | 1.8 | 1.7 | - | 1.9 | 2.0 | 1.9 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.3 | 1.3 | 1.3 | 1.3 | 1.7 | - | 1.7 | 1.7 | 2.5 | 4.9 | 3.8 | 3.2 | 1.7 | 3.2 | 3.2 | 3.2 | 4.9 | 4.9 | 4.9 | 4.9 | 5.5 | 5.5 | 5.5 | 5.5 | 7.6 | 7.6 | 7.6 | 7.6 | 2.3 | 2.3 | 2.3 | 2.3 | 1.8 | 1.8 | 1.8 | 1.8 |
DSO |
61.9 | 94.2 | - | 59.1 | 60.9 | 61.1 | - | 58.0 | 57.5 | 59.7 | - | 54.7 | 52.6 | 55.9 | - | 27.5 | 25.7 | 60.5 | - | 53.4 | 48.6 | 53.9 | 47.1 | 50.3 | 60.2 | 50.1 | 38.6 | 33.2 | 43.7 | 57.1 | 25.1 | - | - | 35.1 | 64.6 | 65.3 | 72.3 | 45.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
107.7 | 135.5 | - | 125.3 | 119.6 | 131.9 | - | 146.8 | 152.1 | 159.8 | - | 110.7 | 105.7 | 102.3 | - | 52.3 | 50.8 | 112.8 | - | 96.1 | 77.7 | 103.8 | - | 91.9 | 115.3 | 88.6 | - | 62.9 | 85.2 | 154.3 | - | 99.2 | 157.4 | 124.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
45.1 | 68.3 | - | 48.5 | 42.4 | 44.9 | - | 43.3 | 53.1 | 65.8 | - | 53.4 | 53.6 | 61.2 | - | 33.0 | 31.3 | 71.2 | - | 78.6 | 62.5 | 74.2 | - | 77.7 | 97.6 | 79.5 | - | 60.2 | 90.8 | 157.2 | - | 92.2 | 146.3 | 72.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 229.6 | - | - | 180.4 | 193.0 | - | 204.8 | 209.5 | 219.5 | - | 165.4 | 158.3 | 158.2 | - | 79.8 | 76.5 | 173.2 | - | 149.5 | 126.3 | 157.7 | 47.1 | 142.2 | 175.6 | 138.7 | 38.6 | 96.1 | 128.9 | 211.4 | 25.1 | 99.2 | 157.4 | 159.2 | 64.6 | 65.3 | 72.3 | 45.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | 161.3 | - | - | 138.0 | 148.2 | - | 161.5 | 156.4 | 153.6 | - | 112.0 | 104.7 | 96.9 | - | 46.8 | 45.2 | 102.0 | - | 70.9 | 63.8 | 83.5 | 47.1 | 64.4 | 78.0 | 59.1 | 38.6 | 35.9 | 38.1 | 54.3 | 25.1 | 7.0 | 11.1 | 86.8 | 64.6 | 65.3 | 72.3 | 45.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company MiMedx Group, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
France
China
Israel
Britain
Canada
